MediciNova, Inc.’s idiopathic pulmonary fibrosis (IPF) drug candidate MN-001 (tipelukast) was recently granted orphan drug status by the US Food and Drug Administration. As a result, MediciNova will have exclusive rights to market MN-001 to treat patients with IPF, should it be approved following clinical trials.
“We are very pleased to receive this orphan-drug designation, which is an important part of our development strategy for MN-001 in IPF,” stated Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova. “As we already have an open investigational new drug (IND) [application], we plan to finalize a protocol and submit it to the FDA in order to conduct a phase 2 clinical trial of MN-001 in IPF.”
MediciNova’s continued success is based on the mechanism of action of MN-001, otherwise known as tipelukast. As an orally active small molecule drug, MN-001 acts through several mechanisms that result in reduced fibrosis and inflammation when used in animal models. The key targets are leukotriene receptor, phosphodiesterases, and 5-lipoxygenase. These molecular pathways may be pathogenic factors in IPF.
According to the company, the 5-LO/LT pathway in MN-001 is believed to be a pathogenic factor in the development of fibrosis. As a result, MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway appears to offer a novel approach to treating fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.
This is not the first time MediciNova has capitalized on MN-001. The company previously demonstrated high efficacy and tolerability of MN-001 in asthmatic patients during phase 2 trials. In total, MN-001 has been used in over 600 participants, with promising results for the intended treatments.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?